Top Markets
Coin of the day
Enzo Biochem, Inc. Enzo Biochem, Inc.

Enzo Biochem, Inc.

ENZ
Rank in Stocks #28166
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics,... Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
Share Price
$0.5495
Last synced: 2025-05-15
Market Cap
$28.14M
Change (1 day)
4.70%
Change (1 year)
0.00%
Country
US
Trade Enzo Biochem, Inc. (ENZ)

Category

P/E ratio for Enzo Biochem, Inc. (ENZ)
P/E ratio as of August 2026 TTM: -0.62
According to Enzo Biochem, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.62. At the end of 2023 the company had a P/E ratio of 3.59.
P/E ratio history for Enzo Biochem, Inc. from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.62 -72.41%
2024 -2.23 -162.05%
2023 3.59 -168.85%
2022 -5.21 -111.36%
2021 45.87 -1,469.40%
2020 -3.35 78.71%
2019 -1.87 -90.67%
2018 -20.09 -90.00%
2017 -200.84 -3,032.49%
2016 6.85 -111.50%
2015 -59.55 190.81%
2014 -20.48 332.49%
2013 -4.73 219.47%
2012 -1.48 -86.89%
2011 -11.31 43.80%
2010 -7.86 -3.16%
2009 -8.12 -83.50%
2008 -49.20 45.77%
2007 -33.75 27.33%
2006 -26.50 -114.85%
2005 178.44 -370.03%
2004 -66.08 -139.03%
2003 169.30 211.46%
2002 54.36 -45.50%
2001 99.74 -51.07%
2000 203.85 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
31.59 -5,234.81%
US
35.83 -5,923.48%
US
- -
CN
-227.89 36,937.17%
US
38.69 -6,388.15%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.